What's new in multiple sclerosis?
| Autor: | Tillery EE; Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina, etill2020@gmail.com., Clements JN; Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina., Howard Z; 3 PGY1 Clinical Pharmacy Resident, Catawba Valley Medical Center, Hickory, North Carolina. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The mental health clinician [Ment Health Clin] 2018 Mar 23; Vol. 7 (5), pp. 213-220. Date of Electronic Publication: 2018 Mar 23 (Print Publication: 2017). |
| DOI: | 10.9740/mhc.2017.09.213 |
| Abstrakt: | Introduction: Multiple sclerosis (MS) is a chronic disease state that affects and disables many people each year. The most common clinical presentation is relapsing-remitting MS (RRMS). In the past 7 years, new medications have been approved for the treatment of RRMS, thereby providing more treatment options for patients and providers. The purpose of this article is to provide an update on medications for the treatment of MS that have been approved since January 2010. Methods: A review was performed utilizing CenterWatch to search for medications approved by the US Food and Drug Administration for the treatment of RRMS between January 2010 and April 2017. The package inserts of medications indicated for RRMS were analyzed, and key points were summarized. PubMed and EBSCOhost were utilized to identify articles relevant to RRMS background and treatment. Results: Seven medications with varying mechanisms of action have been approved to treat RRMS since 2010. Pharmacotherapy options include oral and injectable formulations. Efficacy across the agents is comparable, and each agent has safety data from clinical trials. The safety profile varies between oral and injectable agents, but potential adverse effects are important to consider before initiation. Therapeutic selection is based on patient preference, dosing (frequency and route), and safety considerations. Discussion: Multiple therapeutic options are available for the treatment of RRMS. Health care practitioners should be cognizant of the adverse effects, dosing route, and frequency in order to optimally tailor therapy to meet individual patient needs. Competing Interests: Disclosures: Authors of this manuscript do not have any financial or personal relationships with commercial entities that may have direct or indirect interest in the subject matter of this manuscript. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|